BBP-815

**BBP-815** is an investigational adeno-associated virus gene therapy being developed by BridgeBio for **nonsyndromic hearing loss caused by recessive mutations in the TMC1 gene**. The therapy is intended to deliver a functional copy of **TMC1** to inner-ear sensory hair cells, with the goal of restoring mechanotransduction by replacing defective transmembrane channel-like 1 protein, a key component of the mechanosensory apparatus that converts sound vibrations into electrical signals. The program has been associated with BridgeBio's hearing-loss subsidiary Audition Therapeutics; public pipeline sources have described it as an AAV-based genetic medicine for TMC1-related hearing loss, and some external pipeline aggregators list the program as discontinued.